TNFRSF8 and Hodgkins lymphoma: Another immunotherapy agent that has demonstrated clinical activity in R/R HL is a CD30/CD16A-bispecific antibody, AFM13, which is a first-in-class, tetravalent chimeric antibody (TandAb), manufactured to target CD30+ tumors.